Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 3, 2009, Pages 211-222

  Bellmunt, J ^a   Albiol, S ^a   Suarez C ^a   Albanell, J ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; New agents; Paclitaxel; Urothelial cell cancer

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GALLIUM; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IXABEPILONE; LAPATINIB; LOBAPLATIN; METHOTREXATE; MOLECULAR MARKER; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRITREXIM; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TRIMETREXATE; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

BLADDER CANCER; BLADDER CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYPERCALCEMIA; KIDNEY CARCINOMA; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 63749109609     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.06.002     Document Type: Review

References (135)

1. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
2. Bellmunt J., and Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol 11 (2001) 517-522
3. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
4. Waxman J., and Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 Suppl. C (1993) 21-25
5. Witte R.S., Elson P., Bono B., et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15 (1997) 589-593
6. De Mulder P., Sternberg C., Fossa S., et al. Lobaplatin in advanced urothelial tract tumors (EORTC 30931). Proc Am Soc Clin Oncol (1997) [abstr 1158]
7. de Wit R., Kaye S.B., Roberts J.T., Stoter G., Scott J., and Verweij J. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67 (1993) 388-390
8. Khorsand M., Lange J., Feun L., Clendeninn N.J., and Collier M. Wilding G: phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 15 (1997) 157-163
9. Witte R.S., Elson P., Khandakar J., and Trump D.L. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73 (1994) 688-691
10. Bellmunt J., Albiol S., de Olano A., et al. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 17 (2006) 113-117
11. Dreicer R., Gustin D.M., See W.A., and Williams R.D. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156 (1996) 1606-1608
12. McCaffrey J.A., Hilton S., Mazumdar M., et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15 (1997) 1853-1857
13. Moore M.J., Winquist E., Vokes E.E., et al. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol (2003) [abstr 1638]
14. Misset J.L. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol 29 1 Suppl. 3 (2002) 36-39
15. Vaughn D., Srinvas S., Stadler R., et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol (2007) [abstr 15543]
16. Roth B.J., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264-2270
17. Bellmunt J., and Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol 34 (2007) 135-144
18. Dreicer R., Propert K.J., Roth, Einhorn L.H., and Loehrer P.J. Vinblastine, ifosfamide, and gallium nitrate-an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Cancer 79 1 (1997) 110-114
19. Harker W.G., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3 (1985) 1463-1470
20. Roth B.J., and Bajorin D.F. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153 (1995) 894-900
21. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
22. Boutan-Laroze A., Mahjoubi M., Droz J.P., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur J Cancer 27 (1991) 1690-1694
23. Igawa M., Ohkuchi T., Ueki T., Ueda M., Okada K., and Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144 (1990) 662-665
24. Fossa S.D., Sternberg C., Scher H.I., et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 74 (1996) 1655-1659
25. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
26. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80 (1997) 1966-1972
27. Mead G.M., Russell M., Clark P., et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78 (1998) 1067-1075
28. Loehrer Sr. P.J., Elson P., Dreicer R., et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 12 (1994) 483-488
29. Logothetis C.J., Finn L.D., Smith T., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13 (1995) 2272-2277
30. Scher H.I., Geller N.L., Curley T., and Tao Y. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11 (1993) 400-407
31. Seidman A.D., Scher H.I., Gabrilove J.L., et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11 (1993) 408-414
32. Gabrilove J.L., Jakubowski A., Scher H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318 22 (1988) 1414-1422
33. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
34. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
35. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (1995) 72-79
36. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000) 1921-1927
37. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 (1999) 2876-2881
38. von der Maase H., Andersen L., Crino L., Weinknecht S., and Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10 (1999) 1461-1465
39. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
40. Burch P.A., Richardson R.L., Cha S.S., et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 164 (2000) 1538-1542
41. Dreicer R., Manola J., Roth B.J., Cohen M.B., Hatfield A.K., and Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18 (2000) 1058-1061
42. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol (1996) [abstr 617]
43. Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 10 (1999) 1385-1388
44. Garcia del Muro X., Marcuello E., Guma J., et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86 (2002) 326-330
45. Sengelov L., Kamby C., Lund B., and Engelholm S.A. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16 (1998) 3392-3397
46. Bamias A., Aravantinos G., Deliveliotis C., et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22 (2004) 220-228
47. NCCN Practice Guidelines in Oncology-v.2.2008.
48. Bellmunt J., Albiol S., and Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (2008) 1147-1148
49. Redman B.G., Smith D.C., Flaherty L., Du W., and Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16 (1998) 1844-1848
50. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18 (2000) 2537-2544
51. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16 (1998) 255-260
52. Dreicer R., Manola J., Roth B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004) 1639-1645
53. Bellmunt J., de Wit R., Albanell J., and Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37 (2001) 2212-2215
54. Nogue-Aliguer M., Carles J., Arrivi A., et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97 (2003) 2180-2186
55. Shannon C., Crombie C., Brooks A., Lau H., Drummond M., and Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 12 (2001) 947-952
56. Carteni G., Dogliotti L., Crucitta E., et al. Phase II randomized trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol 22 (2003) 384 [abstr 1543]
57. Petrioli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77 (1996) 344-351
58. Carles J., Esteban E., Climent M., et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 18 (2007) 1359-1362
59. Culine S., Rebillard X., Iborra F., et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res 23 (2003) 1903-1906
60. Theodore C., Bidault F., Bouvet-Forteau N., et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 17 (2006) 990-994
61. Kaufman D.S., Carducci M.A., Kuzel T., et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol (2002) [abstr 767]
62. Li J., Juliar B., Yiannoutsos C., et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23 (2005) 1185-1191
63. Meluch A.A., Greco F.A., Burris III H.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19 (2001) 3018-3024
64. Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., and Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998
65. Kaufman D.S., Carducci M.A., Kuzel T.M., et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22 (2004) 393-397
66. Ardavanis A., Tryfonopoulos D., Alexopoulos A., Kandylis C., Lainakis G., and Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 92 (2005) 645-650
67. Dumez H., Martens M., Selleslach J., et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs 18 (2007) 211-218
68. Gitlitz B.J., Baker C., Chapman Y., et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98 (2003) 1863-1869
69. Li S., Dreicer R., Roth B., et al. Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol (2007) [abstr 5079]
70. von der Maase H., Lehmann J., Gravis G., et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 17 (2006) 1533-1538
71. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671-1678
72. Dodd P.M., McCaffrey J.A., Hilton S., et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18 (2000) 840-846
73. Bajorin D.F., Bellmunt J., Bochner B.H., and Sandler H.M. Changing paradigms in advanced bladder cancer (2005), ASCO Bladder Educational Book
74. Novick S., Higgins G., Hilton S., et al. Phase I/II sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function. Proc Am Soc Clin Oncol (2000) [abstr 1423]
75. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18 (2000) 3247-3255
76. Bellmunt J., von der Maase H., Mead G., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Proc Am Soc Clin Oncol (2007) [LBA5030]
77. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23 (2005) 2903-2910
78. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
79. Hainsworth J.D., Meluch A.A., Litchy S., et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103 (2005) 2298-2303
80. Edelman M.J., Meyers F.J., Miller T.R., Williams S.G., Gandour-Edwards R., and deVere White R.W. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 55 (2000) 521-525
81. Tu S.M., Hossan E., Amato R., Kilbourn R., and Logothetis C.J. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154 (1995) 1719-1722
82. Pectasides D., Visvikis A., Aspropotamitis A., et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 36 (2000) 74-79
83. Law L.Y., Lara P.N., Meyers F.J., et al. Platinum free combination chemotherapy in locally advanced and metastatic transitional cell carcinoma: phase I/II trial of gemcitabine, paclitaxel, methotrexate. Proc Am Soc Clin Oncol (2001) [abstr 767]
84. Bellmunt J., Cos J., Cleries R., et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 20 (2002) 673-685
85. Di Lorenzo G., Autorino R., Giordano A., et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol 34 (2004) 747-750
86. de Wit R., Kruit W.H., Stoter G., de Boer M., Kerger J., and Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78 (1998) 1342-1345
87. Dreicer R., Li S., Manola J., Haas N.B., Roth B.J., and Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 110 (2007) 759-763
88. Kattan J., Culine S., Théodore C., and Droz J.P. Second line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann Oncol 4 9 (1993) 793-794
89. Sweeney C.J., Roth B.J., Kabbinavar F.F., et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24 (2006) 3451-3457
90. Galsky M.D., Mironov S., Iasonos A., Scattergood J., Boyle M.G., and Bajorin D.F. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25 (2007) 265-270
91. Herr H.W., Donat S.M., and Bajorin D.F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol Mar 165 3 (2001) 811-814
92. Siefker-Radtke A.O., Walsh G.L., Pisters L.L., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171 Jan (1) (2004) 145-148
93. Miller R.S., Freiha F.S., Reese J.H., Ozen H., and Torti F.M. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150 July (1) (1993) 65-69
94. Culine S., Theodore C., De Santis M., et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94 (2006) 1395-1401
95. Bellmunt J., Hussain M., and Dinney C.P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46 Suppl. (2003) S85-S104
96. Geller N.L., Sternberg C.N., Penenberg D., Scher H., and Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67 (1991) 1525-1531
97. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
98. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95 (2002) 751-757
99. Bajorin D., Ostrovnaya I., Iasonos A., et al. A nomogram predicting survival or patients with metastatic or unresectable urothelial cancer treated with cisplatin-based chemotherapy. Proc Am Soc Clin Oncol (2007) [abstr 5055]
100. Petrylak D.P., Scher H.I., Reuter V., O'Brien J.P., and Cordon-Cardo C. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5 (1994) 835-840
101. Pendyala L., Velagapudi S., Toth K., et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 3 (1997) 793-798
102. Siu L.L., Banerjee D., Khurana R.J., et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4 (1998) 559-565
103. Duggan B., Kelly J., Keane P.F., Williamson K., and Johnston S.R. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 86 (2000) 757
104. van Brussel J.P., and Mickisch G.H. Circumvention of multidrug resistance in genitourinary tumors. Int J Urol 5 (1998) 1-15
105. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
106. Sarkis A.S., Bajorin D.F., Reuter V.E., et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13 (1995) 1384-1390
107. Inoue K., Kamada M., Slaton J.W., et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8 (2002) 1863-1870
108. Als A.B., Dyrskjot L., von der Maase H., et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13 (2007) 4407-4414
109. Neal D.E., Marsh C., Bennett M.K., et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1 (1985) 366-368
110. Duggan B.J., McKnight J.J., Williamson K.E., et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 9 (2003) 1240-1247
111. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62 (2002) 6973-6980
112. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33 (2003) 90-96
113. Primdahl H., Wikman F.P., von der Maase H., Zhou X.G., Wolf H., and Orntoft T.F. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 94 (2002) 216-223
114. Thykjaer T., Workman C., Kruhoffer M., et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 61 (2001) 2492-2499
115. Sanchez-Carbayo M., and Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 89 (2003) 2172-2177
116. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., and Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24 (2006) 778-789
117. Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97 (2003) 2083-2089
118. Salonga D.S., Danenberg K.D., Grem J., Park J.M., and Danenberg P.V. Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol Biol 191 (2002) 83-98
119. Rosell R., Taron M., Ariza A., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31 (2004) 20-27
120. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., and Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63 (2003) 1311-1316
121. Dabholkar M., Bostick-Bruton F., Weber C., Egwuagu C., Bohr V.A., and Reed E. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 293 (1993) 151-160
122. Britten R.A., Liu D., Tessier A., Hutchison M.J., and Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89 (2000) 453-457
123. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
124. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
125. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
126. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18 (2007) 522-528
127. Ravery V., Grignon D., Angulo J., et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 25 (1997) 9-17
128. Izawa J.I., Slaton J.W., Kedar D., et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 8 (2001) 9-15
129. Rubin M., Shin D., Pasmatier M., et al. Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol (2000) [abstr 474]
130. Philips G.K., Halabi S., Sanford B.L., Bajorin D., and Small E.J. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 101 (2008) 20-25
131. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25 (2007) 2218-2224
132. Beuzeboc P., Banu E., Voog E., et al. Trastuzumab combined with standard chemotherapy in HER + metastatic bladder cancer patients: interim safety results of a prospective randomized phase II study. Proc Am Soc Clin Oncol (2007) [abstr 15565]
133. Wülfing C., Machiels J., Richel D., et al. A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Proc Am Soc Clin Oncol (2005) [abstr 4594]
134. Sonpavde G., Jian W., and Lerner S. Sunitinib malate is active and synergistic with cisplatin against human urothelial carcinoma in a preclinical model. Proc Am Soc Clin Oncol (2007) [abstr 15632]
135. Gallagher D., Milowsky M., Gerst S., et al. Phase II study of sunitinib in patients with relapsed or refractory urothelial. Proc Am Soc Clin Oncol (2007) [abstr 5080]